Case Report 3. Sunitinib malate in patients with cerebellar metastases

European Journal of Cancer, Supplement

Volumn 5, Issue 7, 2007, Pages 32-34

  Négrier, Sylvie ^a  

^a CENTRE LÉON BÉRARD   (France)

Author keywords

Cerebellar tumours; Metastasis; Renal cell carcinoma; Sunitinib malate

Indexed keywords

INTERFERON; SUNITINIB;

ADULT; ARTICLE; ASTHENIA; BRAIN METASTASIS; CANCER GRADING; CANCER PATIENT; CASE REPORT; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ESOPHAGITIS; FEMALE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PLEURA METASTASIS; PRIORITY JOURNAL; SKIN TOXICITY; SPINE METASTASIS; TREATMENT RESPONSE;

EID: 35548953759     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(07)70114-3     Document Type: Article

References (5)

1. Motzer R., Hutson T., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 2 (2007) 115-124
2. Gore M. Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded open access trial with subpopulation analysis. J Clin Oncol 25 18S (2007) 5010
3. Unnithan J., Choueiri T., and Garcia-Saenz J. Safety of VEGF-targeted tyrosine kinase inhibitors in patients (Pts) with metastatic renal cell carcinoma (mRCC) and central nervous system (CNS) metastases. J Clin Oncol 25 18S (2007)
4. Medioni J., Cojocarasu O., Belcaceres J.-L., et al. Complete cerebral response with sunitinib for metastatic renal cell carcinoma. Ann Oncol 18 7 (2007) 1282-1283
5. Patyna S., and Peng G. Distribution of sunitinib and its active metabolite in brain and spinal cord tissue following oral or intravenous administration in rodents and monkeys. Eur J Cancer Suppl 4 12 (2007) 21